Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 896-901

  Chaix, Marie Laure ^a,f   Ekouevi, Didier Koumavi ^b,c   Peytavin, Gilles ^d   Rouet, François ^c   Tonwe Gold, Besigin ^b,e   Viho, Ida ^c,e   Bequet, Laurence ^c   Amani Bosse, Clarisse ^c,e   Menan, Hervé ^c   Leroy, Valériane ^b   Rouzioux, Christine ^a   Dabis, François ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^d BICHAT HOSPITAL   (France)

^e ACONDA   (Côte d’Ivoire)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS DETECTION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MONOCYTES; MUTATION; NEVIRAPINE; PHYLOGENY; PREDICTIVE VALUE OF TESTS; PREGNANCY; RNA, VIRAL;

EID: 33847644552     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00910-06     Document Type: Article

References (31)

1. Barbour, J. D., F. M. Hecht, T. Wrin, T. J. Liegler, C. A. Ramstead, M. P. Busch, M. R. Segal, C. J. Petropoulos, and R. M. Grant. 2004. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18: 1683-1689.
2. Brenner, B., J. P. Routy, Y. Quan, D. Moisi, M. Oliveira, D. Turner, and M. A. Wainberg. 2004. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18:1653-1660.
3. Chaix, M. L., D. Descamps, M. Harzic, V. Schneider, C. Deveau, C. Tamalet, I. Pellegrin, J. Izopet, A. Ruffault, B. Masquelier, L. Meyer, C. Rouzioux, F. Brun-Vezinet, and D. Costagliola. 2003. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 17:2635-2643.
4. Chaix, M. L., D. K. Ekouevi, F. Rouet, B. Tonwe-Gold, I. Viho, L. Bequet, G. Peytavin, H. Toure, H. Menan, V. Leroy, F. Dabis, and C. Rouzioux. 2006. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J. Infect. Dis. 193:482-487.
5. Cressey, T. R., G. Jourdain, M. J. Lallemant, S. Kunkeaw, J. B. Jackson, P. Musoke, E. Capparelli, and M. Mirochnick. 2005. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 38:283-288.
6. Cunningham, C. K., M. L. Chaix, C. Rekacewicz, P. Britto, C. Rouzioux, R. D. Gelber, A. Dorenbaum, J. F. Delfraissy, B. Bazin, L. Mofenson, and J. L. Sullivan. 2002. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J. Infect. Dis. 186:181-188.
7. Dabis, F., L. Bequet, D. K. Ekouevi, I. Viho, F. Rouet, A. Horo, C. Sakarovitch, R. Becquet, P. Fassinou, L. Dequae-Merchadou, C. Welffens-Ekra, C. Rouzioux, and V. Leroy. 2005. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19: 309-318.
8. Devereux, H. L., M. Youle, M. A. Johnson, and C. Loveday. 1999. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13:F123-F127.
9. Eshleman, S. H., L. A. Guay, A. Mwatha, E. R. Brown, S. P. Cunningham, P. Musoke, F. Mmiro, and J. B. Jackson. 2004. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J. Acquir. Immune. Defic. Syndr. 35:126-130.
10. Eshleman, S. H., L. A. Guay, A. Mwatha, S. P. Cunningham, E. R. Brown, P. Musoke, F. Mmiro, and J. B. Jackson. 2004. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res. Hum. Retrovir. 20:595-599.
11. Eshleman, S. H., D. R. Hoover, S. Chen, S. E. Hudelson, L. A. Guay, A. Mwatha, S. A. Fiscus, F. Mmiro, P. Musoke, J. B. Jackson, N. Kumwenda, and T. Taha. 2005. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J. Infect. Dis. 192:30-36.
12. Eshleman, S. H., D. R. Hoover, S. E. Hudelson, S. Chen, S. A. Fiscus, E. Piwowar-Manning, J. B. Jackson, N. I. Kumwenda, and T. E. Taha. 2006. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J. Infect. Dis. 193:479-481.
13. Eshleman, S. H., M. Mracna, L. A. Guay, M. Deseyve, S. Cunningham, M. Mirochnick, P. Musoke, T. Fleming, M. Glenn Fowler, L. M. Mofenson, F. Mmiro, and J. B. Jackson. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-1957.
14. Felsenstein, J. 2001. Taking variation of evolutionary rates between sites into account in inferring phylogenies. J. Mol. Evol. 53:447-455.
15. Flys, T., D. V. Nissley, C. W. Claasen, D. Jones, C. Shi, L. A. Guay, P. Musoke, F. Mmiro, J. N. Strathern, J. B. Jackson, J. R. Eshleman, and S. H. Eshleman. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 192:24-29.
16. Ghosn, J., I. Pellegrin, C. Goujard, C. Deveau, J. P. Viard, J. Galimand, M. Harzic, C. Tamalet, L. Meyer, C. Rouzioux, and M. L. Chaix. 2006. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20:159-170.
17. Johnson, J. A., J. F. Li, L. Morris, N. Martinson, G. Gray, J. McIntyre, and W. Heneine. 2005. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192:16-23.
18. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. Schapiro, A. Telenti, and D. Richman. 2005. Update of the Drug Resistance Mutations in HIV-1: 2005. Top. HIV Med. 13:51-57.
19. Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, and M. Lallemant. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240.
20. Lallemant, M., G. Jourdain, S. Le Coeur, J. Y. Mary, N. Ngo-Giang-Huong, S. Koetsawang, S. Kanshana, K. McIntosh, and V. Thaineua. 2004. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-l in Thailand. N. Engl. J. Med. 351:217-228.
21. McIntyre, J. 2005. Preventing mother-to-child transmission of HIV: successes and challenges. BJOG Int. J. Obstet. Gynaecol. 112:1196-1203.
22. McIntyre, J. 2006. Strategies to prevent mother-to-child transmission of HIV. Curr. Opin. Infect. Dis. 19:33-38.
23. Mirochnick, M., T. Fenton, P. Gagnier, J. Pav, M. Gwynne, S. Siminski, R. S. Sperling, K. Beckerman, E. Jimenez, R. Yogev, S. A. Spector, J. L. Sullivan, et al. 1998. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J. Infect. Dis. 178:368-374.
24. Musoke, P., L. A. Guay, D. Bagenda, M. Mirochnick, C. Nakabiito, T. Fleming, T. Elliott, S. Horton, K. Dransfield, J. W. Pav, A. Murarka, M. Allen, M. G. Fowler, L. Mofenson, D. Hom, F. Mmiro, and J. B. Jackson. 1999. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 13:479-486.
25. Palmer, S., V. Boltz, N. Martinson, F. Maldarelli, G. Gray, J. McIntyre, J. Mellors, L. Morris, and J. Coffin. 2006. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc. Natl. Acad. Sci. USA 103:7094-7099.
26. Rouet, F., M. L. Chaix, A. Inwoley, P. Msellati, I. Viho, P. Combe, V. Leroy, F. Dabis, and C. Rouzioux. 2004. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J. Med. Virol. 74:34-40.
27. Rouet, F., D. K. Ekouevi, M. L. Chaix, M. Burgard, A. Inwoley, T. D. Tony, C. Danel, X. Anglaret, V. Leroy, P. Msellati, F. Dabis, and C. Rouzioux. 2005. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43:2709-2717.
28. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
29. Toni, T., B. Masquelier, D. Bonard, M. Faure, C. Huet, A. Caumont, P. Roques, F. Dabis, R. Salamon, and H. Fleury. 2002. Primary HIV-1 drug resistance in Abidjan (Cote d'Ivoire): a genotypic and phenotypic study. AIDS 16:488-491.
30. Van Heeswijk, R. P., R. M. Hoetelmans, P. L. Meenhorst, J. W. Mulder, and J. H. Beijnen. 1998. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 713:395-399.
31. World Health Organization. 2005. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. World Health Organization, Geneva, Switzerland.